Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
INVESTOR'S BUSINESS DAILY and GLENN LARKIN

AbbVie Stock Shows Rising Relative Strength, Still Has More To Go

On Wednesday, AbbVie got an upgrade to its Relative Strength (RS) Rating, from 68 to 72. While it is on the right track, 80+ is what we are looking for.

When searching for the best stocks to buy and watch, one factor to watch closely is relative price strength.

IBD's unique rating tracks share price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.

Over 100 years of market history shows that the best-performing stocks tend to have an RS Rating north of 80 as they launch their biggest runs. See if AbbVie can continue to rebound and hit that benchmark.

See How IBD Helps You Make More Money In Stocks

AbbVie is trying to complete a flat base with a 168.21 entry. This pattern has formed after a recent cup with handle pattern failed. See if the stock can continue moving in a positive direction and then break out in heavy volume.

AbbVie posted 17% EPS growth in the latest quarterly report. Sales increased 2%.

AbbVie earns the No. 4 rank among its peers in the Medical-Ethical Drugs industry group. Takeda Pharmaceutical ADR is also among the group's highest-rated stocks.

​Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.